This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (47)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Procedures  • Phototherapy  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Alert me on articles by topic  Social Bookmarking   What's this?

Angelika Hofer, MD; Lorenzo Cerroni, MD; Helmut Kerl, MD; Peter Wolf, MD

Arch Dermatol. 1999;135:1377-1380.

Background  Broadband UV-B phototherapy has been used for many years in the treatment of small plaque parapsoriasis (SPP) and early-stage mycosis fungoides (MF). Our purpose was to investigate the effect on these diseases of narrowband (311-nm) UV-B therapy, which was recently established for the treatment of psoriasis and found to be more effective than broadband UV-B therapy.

Observations  Twenty patients (5 women, 15 men; age range, 39-85 years) with histologically confirmed SPP or early-stage MF were enrolled. Six patients had early-stage MF (patch stage), and 14 had SPP. Treatment with 311-nm UV-B was given 3 to 4 times a week for 5 to 10 weeks. In 19 patients, lesions completely cleared after a mean number of 20 treatments (range, 14-29 treatments) and a mean cumulative UV-B dose of 16.3 J/cm² (range, 7.4-36.4 J/cm²) within a mean time of 6 weeks (range, 5-10 weeks). Biopsy specimens taken immediately after the end of phototherapy showed only sparse inflammatory infiltrates but no signs of SPP or MF. Relapses at cutaneous sites occurred in all patients within a mean time of 6 months (range, 2-15 months).

Conclusions  Narrowband UV-B therapy is an effective short-term treatment modality for clearing SPP and early-stage MF. However, the treatment response did not sustain long-term remission. Further studies are necessary to examine how the clinical response to and follow-up after narrowband UV-B therapy compares with that of established phototherapy modalities in these diseases.

From the Department of Dermatology, University of Graz, Graz, Austria.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 1999;135(11):1423-1424.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How I treat mycosis fungoides and Sezary syndrome
Prince et al.
Blood 2009;114:4337-4353.
ABSTRACT | FULL TEXT  

Long-term Follow-up of Patients With Early-Stage Cutaneous T-Cell Lymphoma Who Achieved Complete Remission With Psoralen Plus UV-A Monotherapy
Querfeld et al.
Arch Dermatol 2005;141:305-311.
ABSTRACT | FULL TEXT  

Narrowband (312-nm) UV-B Suppresses Interferon {gamma} and Interleukin (IL) 12 and Increases IL-4 Transcripts: Differential Regulation of Cytokines at the Single-Cell Level
Walters et al.
Arch Dermatol 2003;139:155-161.
ABSTRACT | FULL TEXT  

Narrowband TL-01 Phototherapy for Patch-Stage Mycosis Fungoides
Clark et al.
Arch Dermatol 2000;136:748-752.
ABSTRACT | FULL TEXT  

New Developments in Phototherapy
Journal Watch Dermatology 2000;2000:11-11.
FULL TEXT  

Narrowband UVB Therapy for Early MF
Journal Watch Dermatology 2000;2000:2-2.
FULL TEXT